Study Weighs Timing of Platelet Transfusion With Central Venous Catheter Placement
26 May 2023
Clinical ResultAHA
FRIDAY, May 26, 2023 -- For patients with severe thrombocytopenia, withholding of prophylactic platelet transfusion before ultrasound-guided placement of a central venous catheter (CVC) results in more CVC-related bleeding events than prophylactic platelet transfusion, according to guidelines published in the May 25 issue of the New England Journal of Medicine.
Floor L.F. van Baarle, M.D., from the University of Amsterdam, and colleagues conducted a multicenter, randomized, noninferiority trial involving patients with severe thrombocytopenia (platelet count, 10,000 to 50,000 per mm3) who were treated on the hematology ward or the intensive care unit. Participants were randomly assigned to receive one unit of prophylactic platelet transfusion or no platelet transfusion before ultrasound-guided CVC placement. The per-protocol primary analysis included 373 episodes of CVC placement involving 338 patients. The noninferiority margin was an upper boundary of 3.5 for the 90 percent confidence interval of relative risk.
The researchers found that catheter-related bleeding of grade 2 to 4 occurred in 4.8 and 11.9 percent of patients in the transfusion and no-transfusion groups, respectively (relative risk, 2.45; 90 percent confidence interval, 1.27 to 4.70), and catheter-related bleeding of grade 3 or 4 occurred in 2.1 and 4.9 percent, respectively (relative risk, 2.43; 95 percent confidence interval, 0.75 to 7.93). Overall, there were 15 adverse events reported: 13 were categorized as serious. The net savings were $410 per catheter placement for withholding prophylactic platelet transfusion before CVC placement.
"The noninferiority of withholding transfusion was not shown for the primary outcome of grade 2 to 4 bleeding," the authors write.
The study was funded by ZonMw.
Abstract/Full Text (subscription or payment may be required)
Posted May 2023
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.